Skip to main content
. 2021 Oct 21;12:713007. doi: 10.3389/fphar.2021.713007

FIGURE 2.

FIGURE 2

Rankogram showing the probability analysis of clinical outcomes included among the interventions. LT, low-intensity statins; MT, moderate-intensity statins; HT, high-intensity statins; Eze+MT, ezetimibe + moderate-intensity statins; Eze+HT, ezetimibe + high-intensity statins; P9i+MT, PCSK9i + moderate-intensity statins; P9i+HT, PCSK9i + high-intensity statins; PLBO, placebo.